证券代码：300529 证券简称：健帆生物 公告编号：2025-075 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于 2025 年第三季度健帆转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》等有关规定，健帆生物科技集团股份 有限公司（以下简称"公司"）现将 2025 年第三季度可转换公司债券（以下简 称"健帆转债"）转股及公司股本变化情况公告如下： 一、可转换公司债券发行上市情况 （一）可转换公司债券发行情况 经中国证券监督管理委员会"证监许可[2020]3617 号"文同意注册，健帆生 物科技集团股份有限公司于 2021 年 6 月 23 日向不特定对象发行了 1,000.00 万张 可转换公司债券，每张面值 100 元，发行总额人民币 100,000.00 万元。本次向不 特定对象发行的可转债向公司在股权登记日收市后登记在册的原股东优先配售， 原股东优先配售后余额部分（含原股东放弃优 ...

Core Viewpoint - The article highlights the role of Jianfan Biotechnology Group in promoting health technology in underprivileged areas, emphasizing the company's commitment to social responsibility and community health improvement through its initiatives [1][2]. Group 1: Company Initiatives - Jianfan Biotechnology has identified critical healthcare needs in grassroots regions, such as equipment shortages and difficulties in accessing medical services, and aims to address these through its "light and color" initiatives [1]. - The company has committed to donating over 2.06 million yuan worth of medical supplies, including blood purification machines, to local hospitals in Bijie from 2024 to 2025, enhancing the capacity of blood dialysis services [2]. - In Tibet, Jianfan has pledged a total of 3 million yuan in donations from 2019 to 2025, supporting cataract surgeries for farmers and herders and contributing 500,000 yuan to build a training facility for local medical teams [2]. Group 2: Business and Social Responsibility - The company believes that engaging in social responsibility is not merely a one-way act of giving but a mutual growth opportunity, where both the enterprise and the community benefit [2]. - Jianfan emphasizes the importance of integrating "public welfare logic" with "business logic" to achieve a win-win situation, focusing on using its core strengths to address real pain points in healthcare [3]. - The company advocates for a demand-driven approach to project selection, ensuring that initiatives are based on thorough research to avoid waste and enhance effectiveness [3].

Core Viewpoint - The company reported its sales revenue from high-flow and low-flow dialysis devices and blood dialysis tubing through centralized procurement for the years 2024 and the first half of 2025, indicating a gradual increase in revenue contribution from these products [1] Group 1: Sales Revenue from Centralized Procurement - In 2024, the sales revenue from high-flow and low-flow dialysis devices through centralized procurement was 9.62 million yuan, accounting for 0.36% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in 2024 was 3.36 million yuan, representing 0.13% of the total revenue [1] - For the first half of 2025, the sales revenue from high-flow and low-flow dialysis devices through centralized procurement reached 15.2 million yuan, making up 1.34% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in the first half of 2025 was 2.45 million yuan, which accounted for 0.22% of the total revenue [1] Group 2: Product Inclusion in Centralized Procurement - As of now, the company's main product, blood perfusion devices, has not been included in the centralized procurement scope at the national or provincial levels [1]

Core Viewpoint - The company Jianfan Bio reported a significant reduction in sales expenses for the first half of 2025, indicating improved cost management and operational efficiency [1] Summary by Categories Financial Performance - Sales expenses for the first half of 2025 are projected to be 24.961 million yuan, representing a year-on-year decrease of 26.75% [1]

Core Viewpoint - The company, Jianfan Biological, reported that its overseas market revenue reached 34.44 million yuan in the first half of 2025, accounting for 3.04% of the total company revenue [1] Group 1 - The overseas market revenue for Jianfan Biological in the first half of 2025 was 34.44 million yuan [1] - This overseas revenue represents 3.04% of the company's total revenue [1]

Group 1 - The company has reported overseas revenue of 34.44 million yuan in the first half of 2025, which accounts for 3.04% of its total revenue [2]

Core Viewpoint - The company, Jianfan Biological (300529.SZ), provided insights on its sales performance related to centralized procurement and its overseas market expansion efforts. Group 1: Centralized Procurement Impact - In 2024, the sales revenue from high-flow and low-flow blood dialysis machines through centralized procurement is projected to be 9.62 million yuan, accounting for 0.36% of the total revenue during the same period [1] - The sales revenue from blood dialysis tubing through centralized procurement is expected to be 3.36 million yuan, representing 0.13% of the total revenue [1] - For the first half of 2025, the sales revenue from high-flow and low-flow blood dialysis machines through centralized procurement is anticipated to reach 15.2 million yuan, which will be 1.34% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in the same period is projected to be 2.45 million yuan, accounting for 0.22% of the total revenue [1] - Currently, the company's main product, blood perfusion devices, has not been included in the centralized procurement scope at the national or provincial levels [1] Group 2: Overseas Market Development - In the first half of 2025, the company expects to achieve revenue of 34.44 million yuan from overseas markets, which will constitute 3.04% of the total revenue [1] - The company plans to focus on international market expansion by actively engaging in cross-border research collaborations, refining its overseas distributor network, recruiting overseas marketing personnel, and concentrating on key countries [1] - The strategy aims to tap into overseas market opportunities and drive growth in international business through a dual approach of "chronic diseases + acute critical illnesses" [1]

Core Viewpoint - The company has reported a significant reduction in sales expenses and is adjusting the pricing of its blood perfusion device in response to new healthcare policies in China [1] Group 1: Sales Expenses - In the first half of 2025, the company's sales expenses amounted to 24.961 million yuan, representing a year-on-year decrease of 26.75% [1] Group 2: Policy Impact - The National Healthcare Security Administration issued a guideline in June this year, adding "blood dialysis perfusion fee" and "plasma adsorption fee" as new items, which have been officially included in the medical insurance projects with independent pricing standards [1] - Over twenty provinces in China are actively implementing these policies, which are expected to drive growth in the clinical use of blood perfusion and adsorption products [1] Group 3: Pricing Adjustment - Starting from September 2025, the company will adjust the price of its KHA130 blood perfusion device, which is specifically used for maintenance hemodialysis patients, as part of its commitment to social responsibility and patient care [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-074 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 3、转股价格：38.65 元/股 4、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 5、根据公司《健帆生物科技集团股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）规定：在可转债存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格 低于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交 公司股东大会表决。 自 2025 年 9 月 15 日至 2025 年 9 月 26 日，公司股票已有十个交易日低于当 期转股价格的 85%。若触发转股价格修正条件，公司将按照《募集说明书》的约 定及时履行后续审议程序和信 ...

Group 1 - The core point of the article is that Jianfan Bio has announced the transfer of convertible bonds by its controlling shareholder, Dong Fan, which will take place by September 22, 2025 [2][3] - Dong Fan will transfer a total of 1,264,320 "Jianfan Convertible Bonds," representing 12.64% of the total issued convertible bonds [2]